SLU-PP-332
Preclinical ResearchSLU-PP-332
An ERR agonist (exercise mimetic) that activates the same pathways as endurance exercise without physical activity. Researched for metabolic improvement and heart failure.
Dose
Not established in human research; animal studies often use doses scaled for efficacy, typically in the range of 1-10 mg/kg orally.
Route
Oral
Cycle
Not established in human research; animal studies have used durations ranging from weeks to months.
Storage
Typically stored at -20°C or -80°C for long-term stability. Protect from light and moisture.
What is SLU-PP-332?
SLU-PP-332 is a novel exercise mimetic compound that functions as a potent and selective agonist for all three estrogen-related receptor (ERR) isoforms (ERRα, ERRβ, and ERRγ). Research indicates that SLU-PP-332 activates metabolic pathways similar to those engaged during endurance exercise, without requiring physical activity. This includes promoting mitochondrial biogenesis, enhancing fatty acid oxidation, and improving glucose metabolism. It is primarily being investigated for its potential in treating metabolic disorders, cardiovascular diseases, and conditions where exercise capacity is limited or impaired. Preclinical studies suggest its potential for improving endurance, reducing adiposity, and providing cardioprotective effects.
Key Benefits
- Exercise-like metabolic effects without exercise
- Improved endurance capacity in animals
- Cardiovascular protection
- Fat metabolism improvement
Mechanism of Action
- ERRα/β/γ agonist
- Activates mitochondrial biogenesis
- Mimics exercise adaptation pathways
- PPAR-like effects
Best For
- Metabolic research
- Exercise mimetic research
- Heart failure research
Body Systems
🐾 Griffin Says...
Molecular Information
Type
Small molecule ERR agonist
Research Indications
Exercise-like metabolic effects without physical activity
Activates pathways for mitochondrial biogenesis and fatty acid oxidation, mimicking adaptations to endurance exercise in preclinical models.
Improved glucose metabolism
Research indicates potential for enhanced glucose uptake and utilization, suggesting benefits for conditions involving insulin resistance.
Fat metabolism improvement
Shown to promote the burning of fat for energy, potentially leading to reduced adiposity in animal models.
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Investigate metabolic improvements and fat oxidation | Typically 1-10 mg/kg daily | Once daily | Oral gavage or mixed in feed |
| Assess effects on exercise capacity and endurance | Typically 1-10 mg/kg daily | Once daily | Oral gavage or mixed in feed |
| Study cardiovascular benefits | Typically 1-10 mg/kg daily | Once daily | Oral gavage or mixed in feed |
| Examine mitochondrial biogenesis markers | Typically 1-10 mg/kg daily | Once daily | Oral gavage or mixed in feed |
| Evaluate impact on insulin sensitivity and glucose homeostasis | Typically 1-10 mg/kg daily | Once daily | Oral gavage or mixed in feed |
For oral compounds, consistent daily administration is typically discussed in research protocols to maintain stable compound levels and observe chronic effects.
Peptide Interactions
- Monitor Combination
PPAR agonists (e.g., glitazones, fibrates)
ERRs and PPARs often regulate overlapping metabolic pathways. Co-administration could lead to additive or synergistic effects on lipid and glucose metabolism, requiring careful monitoring in research.
- Use Caution
Mitochondrial uncouplers
Both SLU-PP-332 and mitochondrial uncouplers impact mitochondrial function. The combined effect might excessively stress mitochondrial systems or alter energy expenditure in unexpected ways. Requires careful research.
- Monitor Combination
Insulin sensitizers (e.g., metformin)
Given SLU-PP-332's potential effects on glucose metabolism, co-administration with other insulin-sensitizing agents could lead to enhanced effects on blood glucose levels. Close monitoring in research is advised.
- Monitor Combination
Beta-blockers
Beta-blockers affect cardiovascular function and exercise capacity. The interaction with an exercise mimetic like SLU-PP-332 would require investigation to understand potential counteracting or synergistic effects on cardiac and metabolic parameters.
- Use Caution
Estrogen receptor modulators (SERMs)
While ERRs are distinct from classical estrogen receptors (ERs), they share some regulatory ligands and pathways. Co-administration with SERMs could theoretically lead to complex or unpredictable interactions, particularly concerning hormone-sensitive tissues.
How to Reconstitute
What to Expect
- Weeks 1-2: Initial metabolic shifts, such as changes in substrate utilization, may begin to be observed in animal models.
- Weeks 2-4: Increased mitochondrial markers and improvements in fatty acid oxidation are commonly reported in research.
- Weeks 4-8: Enhanced exercise capacity and endurance parameters, as well as reductions in body fat, have been noted in animal studies.
- Weeks 8-12: More significant cardiovascular benefits and sustained metabolic improvements are often reported in long-term animal research protocols.
- Ongoing: Continued administration typically maintains observed metabolic and performance adaptations in research settings.
Side Effects & Safety
| Effect | Frequency | Severity |
|---|---|---|
| Unknown long-term profile | Unknown | Unknown |
Ready to calculate your dose? Use Griffin's Peptide Calculator 🐾
Open CalculatorPeptides discussed here are for research purposes only. Nothing on this page is medical advice. Always consult a qualified professional before making health decisions.